Glp1 is of particular interest to me because it plays a role in regulating many different metabolic events. Not only does Glp1 stimulate insulin secretion, we believe that it also has direct effects on glucose and fat metabolism, feeding behavior, and cardiac function. Joining Sanford-Burnham allows me to take advantage of different technology cores as well as a collaborative atmosphere to investigate the various actions of Glp1 in the regulation of fuel metabolism.
Dr. Ayala focuses on the role of the incretin hormone glucagon-like peptide-1 (Glp-1) and its receptor in the regulation of fuel metabolism.
Dr. Ayala received his Ph.D. and conducted his post-doctoral studies in molecular physiology and biophysics at Vanderbilt University.
View All Publications
The physiological regulation of glucose flux into muscle in vivo.
Wasserman DH, Kang L, Ayala JE, Fueger PT, Lee-Young RS
J Exp Biol. 2011 Jan 15;214(Pt 2):254-62
Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice.
Ayala JE, Samuel VT, Morton GJ, Obici S, Croniger CM, Shulman GI, Wasserman DH, McGuinness OP, NIH Mouse Metabolic Phenotyping Center Consortium
Dis Model Mech. 2010 Sep-Oct;3(9-10):525-34
Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance.
Ayala JE, Bracy DP, James FD, Burmeister MA, Wasserman DH, Drucker DJ
Endocrinology. 2010 Oct;151(10):4678-87
The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action.
Ayala JE, Bracy DP, James FD, Julien BM, Wasserman DH, Drucker DJ
Endocrinology. 2009 Mar;150(3):1155-64
Glucose metabolism in vivo in four commonly used inbred mouse strains.
Berglund ED, Li CY, Poffenberger G, Ayala JE, Fueger PT, Willis SE, Jewell MM, Powers AC, Wasserman DH
Diabetes. 2008 Jul;57(7):1790-9
Insulin action in the double incretin receptor knockout mouse.
Ayala JE, Bracy DP, Hansotia T, Flock G, Seino Y, Wasserman DH, Drucker DJ
Diabetes. 2008 Feb;57(2):288-97
Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice.
Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT, Wasserman DH
Diabetes. 2007 Apr;56(4):1025-33
Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse.
Ayala JE, Bracy DP, McGuinness OP, Wasserman DH
Diabetes. 2006 Feb;55(2):390-7
Interaction of physiological mechanisms in control of muscle glucose uptake.
Wasserman DH, Ayala JE
Clin Exp Pharmacol Physiol. 2005 Apr;32(4):319-23
Insulin-mediated activation of activator protein-1 through the mitogen-activated protein kinase pathway stimulates collagenase-1 gene transcription in the MES 13 mesangial cell line.
Ayala JE, Boustead JN, Chapman SC, Svitek CA, Oeser JK, Robey RB, O'Brien RM
J Mol Endocrinol. 2004 Aug;33(1):263-80
Julio Ayala's Research Focus
Metabolic Syndrome, Obesity, Type 2 Diabetes, Aging-Related Diseases, Cardiovascular Diseases, Cardiomyopathies, Metabolic Diseases, Diabetes - General
Watch Dr. Ayala describe his research
The growing epidemic of the metabolic syndrome is a critical health care issue affecting the quality of life for millions of individuals. A predominant factor associated with the metabolic syndrome is dysregulated fuel metabolism. The general aim of our research has been to understand the control of inter-organ fuel metabolism with particular emphasis on the regulation of glucose flux by insulin. The approach is to utilize dietary manipulations and pharmacological intervention to perturb metabolic systems in various mouse models. Our laboratory has developed state-of-the-art chronic catheterization techniques that allow for the assessment of insulin action in vivo in unstressed, non-restrained conscious mice using the hyperinsulinemic-euglycemic clamp.
Julio Ayala's Research Report
Glucagon-like peptide-1 (GLP-1) is a gut-secreted peptide that enhances the secretion of insulin from pancreatic beta cells in response to nutrient intake. Because of this incretin effect, GLP-1 action is an attractive target for anti-diabetic therapies. Evidence from our group indicates that signaling through the GLP-1 receptor (Glp1r) also modulates insulin action in the liver and skeletal muscle independent of its ability to stimulate insulin secretion. Interestingly, the Glp1r is not expressed in either the liver or skeletal muscle. However, the Glp1r is expressed in hypothalamic nuclei that play a role in the regulation of glucose homeostasis. The Glp1r is also expressed in brain regions involved in the control of food intake and motivated behavior. Therefore, this presents an exciting opportunity for future research into the role of this incretin hormone to regulate various aspects of fuel metabolism.
About Julio Ayala
Julio Ayala, Ph.D., joined Sanford-Burnham from the Vanderbilt University School of Medicine in Tennessee where he was Research Assistant Professor (2007-2009) in the Department of Molecular Physiology and Biophysics and Technology Transfer Director for the Vanderbilt-NIH Mouse Metabolic Phenotyping Center. Dr. Ayala received his Ph.D. and conducted his post-doctoral studies in molecular physiology and biophysics at Vanderbilt University. His postdoctoral work was at Vanderbilt with Dr. David Wasserman, focusing on regulatory mechanisms that control insulin-stimulated muscle glucose uptake.
B.S., Chemistry, Duke University, 1997
Ph.D., Molecular Physiology & Biophysics, Vanderbilt University School of Medicine, 2003
Adjoint Assistant Professor, Department of Molecular Physiology & Biophysics, Vanderbilt University School of Medicine
Funding Awards and Collaborative Grants
Junior Faculty Award, American Diabetes Association
Honors and Recognition
Vanderbilt University School of Medicine Scholar in Diabetes, 2006
New Investigator Award, American Physiological Society, Endocrinology & Metabolism Section, 2008